<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02208505</url>
  </required_header>
  <id_info>
    <org_study_id>3-2013-0192`</org_study_id>
    <nct_id>NCT02208505</nct_id>
  </id_info>
  <brief_title>Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion</brief_title>
  <official_title>Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion During Emergence in Adults After Thyroidectomy: Comparison With High-dose Remifentanil Infusion Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <brief_summary>
    <textblock>
      After thyroid surgery, the incidence and severity of coughing is important because it may
      cause serious complications, such as bleeding in the surgical field, laryngospasm, and
      cardiovascular disturbance. Several studies have shown that the single-dose of
      dexmedetomidine is effective for reducing cough and agitation during emergence from general
      anesthesia.

      To test the hypothesis that single-dose of dexmedetomidine combined with a low-dose
      remifentanil infusion during emergence from general anaesthesia could reduce coughing as good
      as high-dose remifentanil infusion, we will evaluate the efficacy on cough suppression and
      reduction of side effect of remifentanil using non-inferiority trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of coughing during emergence from general anesthesia</measure>
    <time_frame>from 5min before extubation to 5min after extubation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effect of remifentanil</measure>
    <time_frame>up to 1 day after surgery</time_frame>
    <description>comparison of the incidence of delayed awakening, post-operative nausea/vomiting, consumption of pain killer</description>
  </secondary_outcome>
  <other_outcome>
    <measure>quality of recovery from anesthesia</measure>
    <time_frame>upto 1day after surgery</time_frame>
    <description>using Quality of Recovery-40 questionnaire, evaluate the recovery status of patient from general anesthesia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">168</enrollment>
  <condition>Thyroidectomy</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>we administrate the single-dose dexmedetomidine (0.5mcg/kg) with low-dose remifentanil infusion(TCI 1 ng/ml).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>we administrate the high-dose remifentanil infusion(TCI 2 ng/ml) alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine + Remifentanil-low dose</intervention_name>
    <description>single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil-high dose</intervention_name>
    <description>maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Thyroid disease undergoing thyroidectomy

          -  age 20-65

          -  Amerian society of anesthesgiologist class 1 or 2

        Exclusion Criteria:

          -  chronic cough

          -  difficult intubation

          -  liver disease

          -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeong Soo Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gangnam severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2014</study_first_submitted>
  <study_first_submitted_qc>August 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Jeong Soo Lee</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
    <mesh_term>Antitussive Agents</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

